Clinical Trials Logo

Clinical Trial Summary

The purpose of the trial is to establish whether adjuvant therapy with lenalidomide + dexamethasone after radiotherapy can improve progression free survival in patients with high risk solitary bone plasmacytoma compared with RT only.


Clinical Trial Description

Solitary bone plasmacytoma (SBP) is a localised proliferation of malignant plasma cells (PCs) in the skeleton. The annual UK incidence is 0.4/100,000 (lower than multiple myeloma (MM)) with a peak age incidence at 68 years and there are estimated to be about 260 new cases per year in the United Kingdom (UK). The majority of patients with SBP ultimately progress to myeloma and this is likely due to occult disease not detected by conventional staging methods. Standard care for these patients is involved field radiotherapy (IFRT), but despite radical doses, two-thirds develop multiple myeloma at a median of 2 years, more so if there are high risk features. The IDRIS Trial is a phase III study where the investigators hope to demonstrate that adjuvant lenalidomide + dexamethasone following IFRT prevents the development of multiple myeloma in patients with high risk solitary bone plasmacytoma. Whilst a proportion of solitary bone plasmacytoma is cured with IFRT, it is clear that the majority will progress to multiple myeloma. The investigators are seeking to prevent this outcome by using adjuvant therapy in this study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02544308
Study type Interventional
Source University College, London
Contact
Status Active, not recruiting
Phase Phase 3
Start date March 10, 2017
Completion date December 2026

See also
  Status Clinical Trial Phase
Completed NCT02506959 - Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma Phase 2
Active, not recruiting NCT02921893 - Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome Early Phase 1
Terminated NCT03312868 - Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma Phase 2
Active, not recruiting NCT04174196 - A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma Phase 2
Recruiting NCT06429150 - Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma Phase 1/Phase 2
Recruiting NCT03031730 - Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma Phase 1
Completed NCT02184533 - Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer Phase 1
Completed NCT00421525 - Phase I/II Study of hLL1 in Multiple Myeloma Phase 1/Phase 2
Recruiting NCT04065308 - Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma Phase 2
Completed NCT02547662 - Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia Phase 2
Terminated NCT00109889 - S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma Phase 2